Comparative Pharmacology
Head-to-head clinical analysis: JENCYCLA versus MICROGESTIN FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENCYCLA versus MICROGESTIN FE 1 20.
JENCYCLA vs MICROGESTIN FE 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
None Documented
None Documented
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive